Clinical trial · Interventional
Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer
NCT01691625CI-TRIAL-00073701completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to show if the adoptive cellular therapy with autologous dendritic cells and cytokine-induced killer cells (CIK) combined with concurrent chemoradiation could improve the quality of life of the patients with locally advanced esophageal cancer, compared with concurrent chemoradiation only.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Carcinoma | Esophageal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Concurrent chemoradiation only | Other | — | UNRESOLVED |
| concurrent chemoradiotherapy plus DC-CIK immunotherapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- concurrent chemoradiotherapy plus DC-CIK immunotherapy
- description
- patients will receive concurrent chemoradiotherapy plur DC-CIK immunotherapy
- interventionNames
- Other: concurrent chemoradiotherapy plus DC-CIK immunotherapy
- type
- ACTIVE_COMPARATOR
- label
- Concurrent chemoradiation only
- description
- patients will receive concurrent chemoradiotherapy only
- interventionNames
- Other: Concurrent chemoradiation only
Primary outcomes (1)
- measure
- the quality of life
- timeFrame
- initial assessment, months 1, 3, 6 and 12
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * cytologically or histologically confirmed locally advanced esophageal carcinoma * Age: \> 18 * Karnofsky performance status ≥ 70 * At least one measurable tumor lesions according to the RECIST criteria. * Normal functions of heart, lung, liver, kidney and bone marrow * Blood exams qualified for chemotherapy, which included hemoglobulin ≥9 g/dl, neutrophil ≥1.5×109/L and platelet (PLT) ≥100×109/L, creatinine ≤1.5 UNL * Informed consent signed Exclusion Criteria: * Patients with metastatic disease in the central nervous system (CNS). * Patients who are pregnant or nursing. * Patients with poor bone marrow, liver and kidney functions, which would make chemotherapy intolerable * Patients with contraindication for irradiation: complete obstruction of esophagus, deep esophageal ulcer, fistula to mediastinum, or haematemesis * coexisted morbidities that investigators believed not suitable for chemoradiation
References
Publications (0)
Data not yet available
No reference posted for this study.